ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
ADC Therapeutics (NYSE: ADCT) has announced a conference call and webcast scheduled for December 11, 2024, at 8:30 a.m. EST. The company will present preliminary data from the LOTIS-7 Phase 1b clinical trial, which evaluates ZYNLONTA® in combination with bispecific antibody glofitamab (COLUMVI™) for treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
The conference call will be accessible via toll-free dial-in for North America and Canada participants, and a webcast will be available on the company's investor relations website for 30 days following the presentation.
ADC Therapeutics (NYSE: ADCT) ha annunciato una conference call e un webcast programmati per l'11 dicembre 2024, alle 8:30 a.m. EST. La società presenterà dati preliminari del trial clinico LOTIS-7 di fase 1b, che valuta ZYNLONTA® in combinazione con l'anticorpo bispecifico glofitamab (COLUMVI™) per il trattamento del linfoma diffuso a grandi cellule B (DLBCL) in fase di recidiva o refrattario (r/r DLBCL).
La conference call sarà accessibile tramite numero verde per i partecipanti del Nord America e del Canada, e un webcast sarà disponibile sul sito delle relazioni con gli investitori della società per 30 giorni dopo la presentazione.
ADC Therapeutics (NYSE: ADCT) ha anunciado una conferencia telefónica y un webcast programados para el 11 de diciembre de 2024, a las 8:30 a.m. EST. La empresa presentará datos preliminares del ensayo clínico LOTIS-7 de fase 1b, que evalúa ZYNLONTA® en combinación con el anticuerpo bispecífico glofitamab (COLUMVI™) para el tratamiento del linfoma difuso de células B grandes (DLBCL) en recaída o refractario (r/r DLBCL).
La conferencia telefónica será accesible mediante una línea gratuita para los participantes de América del Norte y Canadá, y un webcast estará disponible en el sitio web de relaciones con inversores de la empresa durante 30 días después de la presentación.
ADC 테라퓨틱스(NYSE: ADCT)는 2024년 12월 11일 오전 8시 30분 EST에 예정된 컨퍼런스 콜과 웹캐스트를 발표했습니다. 회사는 LOTIS-7 1b 임상 시험의 초기 데이터를 발표할 예정이며, 이는 ZYNLONTA®와 이중 작용 항체 glofitamab(COLUMVI™)의 병용 요법으로 재발성 또는 불응성 확산 대세포 B 림프종(r/r DLBCL) 치료를 평가합니다.
컨퍼런스 콜은 북미 및 캐나다 참가자들을 위한 수신자 부담 전화로 접근 가능하며, 발표 후 30일 동안 회사의 투자자 관계 웹사이트에서 웹캐스트를 이용할 수 있습니다.
ADC Therapeutics (NYSE: ADCT) a annoncé une conférence téléphonique et un webinaire prévus pour le 11 décembre 2024 à 8h30 EST. L'entreprise présentera des données préliminaires de l'essai clinique LOTIS-7 de phase 1b, qui évalue ZYNLONTA® en combinaison avec l'anticorps bispécifique glofitamab (COLUMVI™) pour le traitement du lymphome diffus à grandes cellules B (DLBCL) en rechute ou réfractaire (r/r DLBCL).
La conférence téléphonique sera accessible via un numéro gratuit pour les participants d'Amérique du Nord et du Canada, et un webinaire sera disponible sur le site des relations investisseurs de l'entreprise pendant 30 jours après la présentation.
ADC Therapeutics (NYSE: ADCT) hat eine Telefonkonferenz und einen Webcast für den 11. Dezember 2024 um 8:30 Uhr EST angekündigt. Das Unternehmen wird vorläufige Daten aus der LOTIS-7 Phase 1b-Studie präsentieren, die ZYNLONTA® in Kombination mit dem bispezifischen Antikörper glofitamab (COLUMVI™) zur Behandlung von rezidivierenden oder refraktären diffusen großzelligen B-Zell-Lymphomen (r/r DLBCL) bewertet.
Die Telefonkonferenz ist über eine gebührenfreie Einwahl für Teilnehmer aus Nordamerika und Kanada zugänglich, und ein Webcast wird auf der Unternehmenswebsite für Investorenbeziehungen 30 Tage nach der Präsentation verfügbar sein.
- None.
- None.
Company to host corporate update webcast to share results on December 11, 2024
LAUSANNE,
To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle),
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-provide-initial-data-update-on-lotis-7-clinical-trial-302324496.html
SOURCE ADC Therapeutics SA
FAQ
What is the purpose of ADC Therapeutics' LOTIS-7 Phase 1b trial?
When will ADCT present the LOTIS-7 trial preliminary data?
How can investors access ADCT's LOTIS-7 data presentation?
